Grifols (NASDAQ:GRFS) Trading 2.2% Higher

Grifols, S.A. (NASDAQ:GRFS)’s share price shot up 2.2% during mid-day trading on Tuesday . The stock traded as high as $7.34 and last traded at $7.34. 572,556 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 2,175,915 shares. The stock had previously closed at $7.18.

Grifols Price Performance

The company has a quick ratio of 1.29, a current ratio of 1.68 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $4.94 billion, a PE ratio of 7.18 and a beta of 0.49. The firm’s fifty day simple moving average is $7.38 and its 200-day simple moving average is $7.25.

Grifols (NASDAQ:GRFS) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). Grifols had a net margin of 0.90% and a return on equity of 1.73%. The company had revenue of $1.96 billion for the quarter. On average, research analysts forecast that Grifols, S.A. will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GRFS. QRG Capital Management Inc. increased its holdings in Grifols by 5.9% during the fourth quarter. QRG Capital Management Inc. now owns 35,116 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 1,964 shares during the last quarter. Team Hewins LLC increased its holdings in Grifols by 11.8% during the first quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 4,324 shares during the last quarter. Bank of Montreal Can increased its holdings in Grifols by 12.4% during the second quarter. Bank of Montreal Can now owns 70,640 shares of the biotechnology company’s stock valued at $446,000 after buying an additional 7,786 shares during the last quarter. Capital Group Investment Management PTE. LTD. boosted its position in shares of Grifols by 11.8% in the first quarter. Capital Group Investment Management PTE. LTD. now owns 81,955 shares of the biotechnology company’s stock worth $547,000 after purchasing an additional 8,660 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Grifols by 66.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 9,350 shares during the period.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.